You have read all your free articles, to continue reading subscribe to read the rest of this content.
Cyxone has received approvals from the Medical Product Agency and the Central Ethics Committee in Poland to start a clinical Phase 2b study with its drug candidate Rabeximod, which is being developed as a treatment for rheumatoid arthritis (RA). “The approval is a very important milestone for uAlready a subscriber…
Galecto's oral small molecule galectin-3 inhibitor, GB1211, was well tolerated in pre-clinical and Phase 1 studies and is ready to start a Phase 2a clinical study to treat liver fibrosis in Non-Alcoholic SteatoHepatitis (NASH). GB1211 has been shown to be effective in several pre-clinical fibrosiAlready a subscriber Login You have…
The first patient has been successfully dosed in the Phase I study with the wholly owned 4-1BB antibody ATOR-1017, which is being developed for the treatment of metastasized cancer. The Phase I study is a dose escalation study in patients with advanced cancer and this is the first time ATOR-1017…
Finnish Biotie announces start of tozadenant Phase 3 Study of tozadenant, an investigational adenosine A2a receptor antagonist, in patients with Parkinson's disease experiencing levodopa related end-of-dose "wearing-off". The Phase 3 study (TOZ-PD) is a randomized, double-blind, placebo controlledAlready a subscriber Login You have read all your free articles, to continue…
